DC Chemicals

All products / DC8476

ACY-738
CAT. NO. DC8476

ACY-738

Pack sizes and prices

Pack sizePrice
100 mg$550 USDRequest a quote →
250 mg$1,000 USDRequest a quote →
1 g$1,900 USDRequest a quote →

In stock. Contact our team for lead time, shipping and final quotation.

Product overview

ACY-738 is a potent, selective and orally-bioavailable HDAC6 inhibitor, with an IC50s of 1.7 nM; ACY-738 also inhibits HDAC1, HDAC2, and HDAC3, with IC50s of 94, 128, and 218 nM.

For research use only. Results depend on experimental conditions and do not constitute a performance guarantee.

Identity and specifications

Catalog numberDC8476
Product nameACY-738
CAS1375465-91-0
Molecular formulaC14H14N4O2
Molecular weight270.2866
Purity>98%
SMILESO=C(C1=C([H])N=C(N=C1[H])N([H])C1(C2C([H])=C([H])C([H])=C([H])C=2[H])C([H])([H])C1([H])[H])N([H])O[H]

Source-listed specifications; the batch COA applies.

Source and product documents

The supplier source is linked below. Contact us for COA, SDS and batch-specific documents.

DC Chemicals — ACY-738 (DC8476)

Source references

[1]. Jochems J, et al. Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability. Neuropsychopharmacology. 2014 Jan;39(2):389-400. [2]. Regna NL, et al. Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice. Clin Immunol. 2016 Jan;162:58-73. [3]. Mithraprabhu S, et al. Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC. Br J Haematol. 2013 Aug;162(4):559-62.

Related research products